Literature DB >> 30190343

ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study.

Paolo Strati1, Michelle A Fanale2,3, Yasuhiro Oki2, Francesco Turturro2, Luis E Fayad2, Nancy L Bartlett4, Douglas E Gladstone5, Yvette L Kasamon5, Carol S Portlock6, Wyndham H Wilson7, Andre Goy8, Anas Younes6, Hun Ju Lee9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30190343      PMCID： PMC6355491          DOI： 10.3324/haematol.2018.199844

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  Neutropenia in patients treated with rituximab.

Authors:  Eric Voog; Franck Morschhauser; Philippe Solal-Céligny
Journal:  N Engl J Med       Date:  2003-06-26       Impact factor: 91.245

2.  Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma.

Authors:  Yvette L Kasamon; Heather A Jacene; Christopher D Gocke; Lode J Swinnen; Douglas E Gladstone; Brandy Perkins; Brian K Link; Leslie L Popplewell; Thomas M Habermann; Joseph M Herman; William H Matsui; Richard J Jones; Richard F Ambinder
Journal:  Blood       Date:  2012-02-16       Impact factor: 22.113

3.  Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma.

Authors:  Michelle A Fanale; Chan Yoon Cheah; Amy Rich; L Jeffrey Medeiros; Chao-Ming Lai; Yasuhiro Oki; Jorge E Romaguera; Luis E Fayad; F B Hagemeister; Felipe Samaniego; Maria A Rodriguez; Sattva S Neelapu; Hun J Lee; Loretta Nastoupil; Nathan H Fowler; Francesco Turturro; Jason R Westin; Michael L Wang; Peter McLaughlin; Chelsea C Pinnix; Sarah A Milgrom; Bouthaina Dabaja; Sandra B Horowitz; Anas Younes
Journal:  Blood       Date:  2017-05-18       Impact factor: 22.113

4.  Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses.

Authors:  Andrea Gallamini; Caterina Patti; Simonetta Viviani; Andrea Rossi; Francesca Fiore; Francesco Di Raimondo; Maria Cantonetti; Caterina Stelitano; Tatyana Feldman; Paolo Gavarotti; Roberto Sorasio; Antonino Mulè; Monica Leone; Alessandro Rambaldi; Alberto Biggi; Sally Barrington; Federico Fallanca; Umberto Ficola; Stéphane Chauvie; Alessandro Massimo Gianni
Journal:  Br J Haematol       Date:  2010-12-20       Impact factor: 6.998

5.  Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group.

Authors:  M Loeffler; O Brosteanu; D Hasenclever; M Sextro; D Assouline; A A Bartolucci; P A Cassileth; D Crowther; V Diehl; R I Fisher; R T Hoppe; P Jacobs; J L Pater; S Pavlovsky; E Thompson; P Wiernik
Journal:  J Clin Oncol       Date:  1998-03       Impact factor: 44.544

6.  Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group.

Authors:  Peter Borchmann; Heinz Haverkamp; Andreas Lohri; Ulrich Mey; Stefanie Kreissl; Richard Greil; Jana Markova; Michaela Feuring-Buske; Julia Meissner; Ulrich Dührsen; Helmut Ostermann; Ulrich Keller; Georg Maschmeyer; Georg Kuhnert; Markus Dietlein; Carsten Kobe; Hans Eich; Christian Baues; Harald Stein; Michael Fuchs; Volker Diehl; Andreas Engert
Journal:  Lancet Oncol       Date:  2017-02-22       Impact factor: 41.316

7.  A pilot study of rituximab in patients with recurrent, classic Hodgkin disease.

Authors:  Anas Younes; Jorge Romaguera; Frederick Hagemeister; Peter McLaughlin; Maria Alma Rodriguez; Paolo Fiumara; Andre Goy; Sima Jeha; John T Manning; Dan Jones; Lynne V Abruzzo; L Jeffrey Medeiros
Journal:  Cancer       Date:  2003-07-15       Impact factor: 6.860

8.  B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models.

Authors:  Samuel Kim; Zvi G Fridlender; Robert Dunn; Marilyn R Kehry; Veena Kapoor; Aaron Blouin; Larry R Kaiser; Steven M Albelda
Journal:  J Immunother       Date:  2008-06       Impact factor: 4.456

Review 9.  Clinicopathologic and molecular features of Hodgkin's lymphoma.

Authors:  Anas Younes; Antonio Carbone
Journal:  Cancer Biol Ther       Date:  2003 Sep-Oct       Impact factor: 4.742

10.  Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group.

Authors:  Ute Rehwald; Holger Schulz; Marcel Reiser; Markus Sieber; Jan Oliver Staak; Franck Morschhauser; Christoph Driessen; Thomas Rudiger; Konrad Muller-Hermelink; Volker Diehl; Andreas Engert
Journal:  Blood       Date:  2003-01-15       Impact factor: 22.113
View more
  6 in total

1.  Methotrexate-associated Classical Hodgkin Lymphoma Shows Distinct Clinicopathological Features but Comparable Clinical Outcomes With Sporadic Cases.

Authors:  Kota Yoshifuji; Yoshihiro Umezawa; Ayako Ichikawa; Ken Watanabe; Osamu Miura; Masahide Yamamoto
Journal:  In Vivo       Date:  2019 Sep-Oct       Impact factor: 2.155

2.  Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin's lymphoma: a phase II, non-randomized controlled trial.

Authors:  Jessica Hochberg; Jaclyn Basso; Qiuhu Shi; Liana Klejmont; Allyson Flower; Kristina Bortfeld; Lauren Harrison; Carmella van de Ven; Chitti Moorthy; Humayun Islam; Perry Gerard; Stephan Voss; Mitchell S Cairo
Journal:  J Immunother Cancer       Date:  2022-05       Impact factor: 12.469

Review 3.  Extending the Promise of Chimeric Antigen Receptor T-Cell Therapy Beyond Targeting CD19+ Tumors.

Authors:  Natalie S Grover; Nicholas Tschernia; Gianpietro Dotti; Barbara Savoldo
Journal:  J Clin Oncol       Date:  2021-01-12       Impact factor: 44.544

Review 4.  Immune and Inflammatory Cells of the Tumor Microenvironment Represent Novel Therapeutic Targets in Classical Hodgkin Lymphoma.

Authors:  Eleonora Calabretta; Francesco d'Amore; Carmelo Carlo-Stella
Journal:  Int J Mol Sci       Date:  2019-11-05       Impact factor: 5.923

5.  Impact of cluster of differentiation 20 expression and rituximab therapy in classical Hodgkin lymphoma: Real world experience.

Authors:  Khadega A Abuelgasim; Raed Al Shammari; Saeed Alshieban; Bader Alahmari; Mohsen Alzahrani; Ayman Alhejazi; Ahmed Alaskar; Moussab Damlaj
Journal:  Leuk Res Rep       Date:  2021-04-08

6.  CD20 expression is closely associated with Epstein-Barr virus infection and an inferior survival in nodular sclerosis classical Hodgkin lymphoma.

Authors:  Xia Zhao; Yushuo Ma; Haiyan Bian; Zhihe Liu
Journal:  Front Oncol       Date:  2022-09-06       Impact factor: 5.738
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.